Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Single-arm Phase II Clinical Study to Evaluate the Efficacy of Camrelizumab in Combined With APatinib and Albumin Paclitacxel in Advanced Untreated EGFR Wild Type and ALK-negative Lung Adenocarcinoma

NCT04459078 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.

NCT NCT04459078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04459078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Single-arm Phase II Clinical Study to Evaluate the Efficacy of Camrelizumab in Combined With APatinib and Albumin Paclitacxel in Advanced Untreated EGFR Wild Type and ALK-negative Lung Adenocarcinoma
Lead sponsor
Hunan Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
August 26, 2020
Completion date
July 15, 2023
Enrollment
63 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the lung